Compare EXK & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXK | OCUL |
|---|---|---|
| Founded | 1981 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2004 | 2014 |
| Metric | EXK | OCUL |
|---|---|---|
| Price | $8.33 | $9.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $13.94 | ★ $23.56 |
| AVG Volume (30 Days) | ★ 7.0M | 2.9M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,990,000.00 |
| Revenue This Year | $69.59 | $7.93 |
| Revenue Next Year | $17.61 | $96.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.48 |
| 52 Week Low | $4.75 | $6.23 |
| 52 Week High | $15.15 | $16.44 |
| Indicator | EXK | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 57.89 |
| Support Level | $7.12 | $7.92 |
| Resistance Level | $8.36 | $9.93 |
| Average True Range (ATR) | 0.50 | 0.59 |
| MACD | -0.02 | 0.12 |
| Stochastic Oscillator | 39.78 | 63.05 |
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has three operating mining segments namely; Guanacevi and Terronera in Mexico, and Minera Kolpa in Peru. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.